Merck & Co.

Leadership as listed on merck.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Products and services as listed on merck.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

What public registers list for Merck & Co. (MSD) (group figures): clinical trials it sponsors, FDA device clearances, Irish licences, recent approvals and supply shortages. Rebuilt daily, last on 7 Oct 2026.

Clinical trials 205 in our ClinicalTrials.gov registers · 13 in the EU register

Showing 10 of 205, trials with Irish sites first. The full lists are on the sponsor pages below.

All trials by sponsor name 1 registry name

Drugs in these trials 145 compounds

EU trials register (CTIS) 13 authorised or ongoing · 1 in Ireland

• A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Crohn’s Disease2024-518296-56-00 · Phase III · Ongoing · site in Ireland
• A clinical trial of MK-3586 in healthy participants (MK-3586-001)2026-527250-39-00 · Phase I · Authorised
• LIGHTBEAM-U01 Substudy 01D: A Phase 1b/2 Substudy to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors2025-522339-32-00 · Phase I/II · Ongoing
• A clinical trial of MK-1824 in healthy participants (MK-1824-002)2026-527518-22-00 · Phase I · Ongoing
• Phase 1/2 Study of Intravesical MK-3120 in BCG-Naïve or BCG-Exposed High-Risk Non-muscle Invasive Bladder Cancer2025-520467-40-00 · Phase I/II · Ongoing
• A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Adult Participants with Moderately to Severely Active Ulcerative Colitis2025-523479-49-00 · Phase II · Ongoing
• A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012).2024-517232-22-00 · Phase III · Ongoing
• A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)2025-522643-18-00 · Phase III · Ongoing

Recent approvals

• EnflonsiaEMA · clesrovimab · 15 Apr 2026

Medicine shortages 6 in the FDA list · 1 German notices

• Ivermectin TabletUS (FDA) · resolved · updated 29 Sep 2026
• Imipenem Anhydrous, Cilastatin, and Relebactam Anhydrous InjectionUS (FDA) · resolved · updated 9 Sep 2026
• Aprepitant Oral Powder for SuspensionUS (FDA) · resolved · updated 8 Apr 2026
• Imipenem and Cilastatin InjectionUS (FDA) · resolved · updated 8 Jan 2026
• Posaconazole InjectionUS (FDA) · resolved · updated 2 Dec 2025
• Elbasvir; Grazoprevir TabletUS (FDA) · resolved · updated 17 Oct 2025
• NoxafilGermany (BfArM) · 2 Sep 2026 to 30 Oct 2026

A company is listed here when it is named on the shortage record; a shortage can have several manufacturers. See the US and German shortage trackers.

NICE technology appraisals 44 of its medicines · 44 current

• Pembrolizumab with chemoradiotherapy for untreated locally advanced cervical cancerNICE TA1177 · Recommended · 14 Jul 2026
• Sotatercept for treating pulmonary arterial hypertensionNICE TA1161 · Optimised · 3 Jun 2026
• Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinomaNICE TA1145 · Recommended · 21 Apr 2026
• Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma (terminated appraisal)NICE TA1125 · Terminated (no company submission) · 27 Jan 2026
• Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancerNICE TA1092 · Recommended · 27 Aug 2025
• Letermovir for preventing cytomegalovirus infection after a kidney transplant (terminated appraisal)NICE TA1082 · Terminated (no company submission) · 23 Jul 2025
• Molnupiravir for treating COVID-19NICE TA1056 · Optimised · 16 Apr 2025
• Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancerNICE TA1037 · Recommended · 5 Feb 2025

Appraisals of medicines sold under a brand this company holds in EMA or FDA records, from our NICE appraisals register. NICE decisions apply to the NHS in England. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Group (Merck & Co. (MSD)): founded 1891, headquarters Rahway, website merck.com. Wikidata Q247489 · Wikipedia. From Wikidata (CC0), matched by the group's SEC filer number.

How this is matched: register records are linked to this page by the organisation name they carry, here Merck Sharp & Dohme LLC; Merck Sharp & Dohme BV; Merck Sharp & Dohme BV,; Merck Sharp & Dohme Ireland (Human Health) Limited; Merck Sharp Dohme Limited; Merck Sharp & Dohme Corp. and 3 more. Spot a wrong match? Tell us.

From the annual reports Merck & Co., Inc. (MSD) files with the US Securities and Exchange Commission (10-K, US GAAP), in USD as reported. Latest financial year: to Dec 2025.

Each year is taken from the most recent annual report that includes it, so earlier years reflect any later restatement. Source: SEC EDGAR (XBRL financial data). Compare companies on the pharma company financials register.

Companies registered in Ireland 12 active in the CRO register · 1 dissolved not shown

From the Companies Registration Office (CRO Open Data, CC BY 4.0). A company is listed when GLEIF's legal entity register links it to Merck & Co., Inc. (MSD) as its ultimate parent, or when we checked its name and registered address by hand. Branches of foreign companies appear as "External company". Spot a missing or wrong entry? Tell us.